Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carbamazepine
Drug ID BADD_D00356
Description Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.[L1335] Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.[A180319]
Indications and Usage Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia.[L1335] In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures.[A180301,L1335] Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder.[L1335] Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.[A180415,A180421]
Marketing Status approved; investigational
ATC Code N03AF01
DrugBank ID DB00564
KEGG ID D00252
MeSH ID D002220
PubChem ID 2554
TTD Drug ID D04MSM
NDC Product Code 62512-0024; 30698-421; 50268-172; 60687-583; 63629-9292; 66993-409; 70518-3266; 70771-1470; 0615-8125; 0781-5987; 0904-6885; 49452-1705; 63552-060; 0078-0510; 0078-0511; 16571-681; 16714-064; 0093-0778; 17856-0029; 29033-019; 30698-419; 35561-355; 50090-0384; 51672-4047; 51672-4151; 54092-173; 60429-934; 60687-594; 63629-8721; 70518-0181; 70771-1469; 70954-240; 71205-025; 75834-220; 12658-0525; 12658-0526; 0904-7116; 42419-014; 35561-357; 51672-4149; 54092-171; 59746-789; 60505-2805; 63629-8743; 66993-407; 67386-621; 68788-7210; 70518-1433; 59746-790; 63629-8753; 68084-562; 68382-557; 70518-3176; 0781-5988; 16714-063; 27241-233; 29033-004; 29300-382; 35561-356; 51407-215; 60505-2807; 70518-1545; 71930-073; 72162-2021; 0781-8016; 0832-6022; 12658-0561; 12658-0565; 48087-0051; 70966-0020; 76003-0251; 13668-268; 0093-0109; 27241-232; 43063-328; 50268-170; 54092-172; 60505-2806; 68788-7825; 70518-1436; 70518-2242; 70518-3335; 71335-0461; 71335-0691; 71930-072; 75834-221; 0904-3854; 51927-2176; 13668-271; 51672-4125; 63629-8715; 68084-444; 68382-555; 70518-1769; 70518-2456; 70518-3699; 70518-3773; 0832-6023; 12658-0452; 51552-0653; 62991-1027; 65344-0028; 65344-0040; 0078-0512; 27241-231; 0121-0947; 43353-953; 59746-791; 70518-2426; 70518-3146; 71930-074; 72189-157; 0904-6172; 12658-0406; 12658-0541; 0078-0509; 0093-0090; 29033-020; 51672-4005; 51672-4123; 55154-1396; 60505-0183; 60687-479; 63629-8720; 68094-007; 68382-556; 70518-2841; 70518-3591; 70518-3694; 71335-1730; 12658-0486; 38779-0114; 48087-0052; 0078-0508; 16714-065; 30698-423; 50268-171; 51672-4150; 58118-0268; 66993-408; 68071-2701; 70518-2489; 70518-3174; 70771-1468; 0615-3505; 72664-218; 0832-6024; 65372-1102; 16571-680; 16571-682; 0121-1894; 50090-5740; 51672-4041; 51672-4124; 60429-032
UNII 33CM23913M
Synonyms Carbamazepine | Carbamazepine Acetate | Carbamazepine Dihydrate | Carbamazepine Hydrochloride | Carbamazepine L-Tartrate (4:1) | Carbamazepine Anhydrous | Carbamazepine Sulfate (2:1) | Carbazepin | Epitol | Finlepsin | Neurotol | Tegretol | Amizepine | Carbamazepine Phosphate
Chemical Information
Molecular Formula C15H12N2O
CAS Registry Number 298-46-4
SMILES C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gaze palsy17.02.05.044; 06.05.02.0140.000372%Not Available
Colitis microscopic07.08.01.0110.000186%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000279%Not Available
Anxiety disorder19.06.01.0020.000279%Not Available
Bipolar disorder19.16.01.0030.000372%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.002734%
Toxic skin eruption23.03.05.003; 10.01.01.008; 12.03.01.0730.002697%Not Available
Metabolic disorder14.11.01.0010.000186%Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.000372%Not Available
Pulseless electrical activity02.03.04.0200.000279%Not Available
Dysgraphia17.02.03.0060.000186%Not Available
Bicytopenia01.03.03.0100.000186%Not Available
Bone metabolism disorder14.04.04.009; 15.02.03.009--Not Available
Venous occlusion24.04.02.0090.000186%Not Available
Cluster headache17.14.01.0030.000186%Not Available
Angiopathy24.03.02.007--Not Available
Epidermal necrosis23.03.03.0350.000186%Not Available
Protein-losing gastroenteropathy14.03.02.015; 07.11.01.0130.000186%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.005--Not Available
Neurological symptom17.02.05.0100.000279%Not Available
Bladder disorder20.03.01.0020.000186%Not Available
Brain neoplasm17.20.01.003; 16.30.01.0030.000372%Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Eye movement disorder06.05.02.008; 17.02.05.0250.000874%Not Available
Eyelid function disorder06.05.01.0030.000186%
Feeding disorder14.03.02.003; 19.09.01.0030.001153%Not Available
Finger deformity15.10.03.0030.000186%Not Available
Embolism24.01.01.009--
The 25th Page    First    Pre   25 26 27 28 29    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene